Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA

JACC: Cardiovascular Imaging

Volumn 11, Issue 2P1, 2018, Pages 221-230

  Mortensen, Martin Bødtker ^a   Falk, Erling ^a   Li, Dong ^b   Nasir, Khurram ^c,d,e   Blaha, Michael J ^e   Sandfort, Veit ^f   Rodriguez, Carlos Jose ^g   Ouyang, Pamela ^h   Budoff, Matthew ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MIAMI CANCER INSTITUTE   (United States)

^d FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease; guideline; lipoproteins; primary prevention; statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCTION (CHEMISTRY); RISK FACTOR; RISK REDUCTION; BLOOD VESSEL CALCIFICATION; CLINICAL DECISION MAKING; CLINICAL TRIAL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DYSLIPIDEMIA; EPIDEMIOLOGY; ETHNOLOGY; EVIDENCE BASED MEDICINE; MIDDLE AGED; MULTICENTER STUDY; PATIENT SELECTION; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CLINICAL DECISION-MAKING; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PATIENT SELECTION; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VASCULAR CALCIFICATION;

EID: 85020803338     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2017.01.029     Document Type: Article

References (40)

1. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
2. Piepoli, M.F., Hoes, A.W., Agewall, S., et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 37 (2016), 2315–2381.
3. JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 100:Suppl 2 (2014), ii1–ii67.
4. Ridker, P.M., Wilson, P.W.F., A trial-based approach to statin guidelines. JAMA 310 (2013), 1123–1124.
5. Ridker, P.M., Cook, N.R., Statins: new American guidelines for prevention of cardiovascular disease. Lancet 382 (2013), 1762–1765.
6. Ridker, P.M., Rose, L., Cook, N.R., A Proposal to incorporate trial data into a hybrid ACC/AHA algorithm for the allocation of statin therapy in primary prevention. J Am Coll Cardiol 65 (2015), 942–948.
7. Ridker, P.M., What works and in whom? A simple, easily applied, evidence-based approach to guidelines for statin therapy. Circ Cardiovasc Qual Outcomes 5 (2012), 592–593.
8. Mortensen, M.B., Afzal, S., Nordestgaard, B.G., Falk, E., Primary prevention with statins: ACC/AHA risk-based approach versus trial-based approaches to guide statin therapy. J Am Coll Cardiol 66 (2015), 2699–2709.
9. Bild, D.E., Bluemke, D.A., Burke, G.L., et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol 156 (2002), 871–881.
10. Shepherd, J., Cobbe, S.M., Ford, I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995), 1301–1307.
11. Downs, J.R., Clearfield, M., Weis, S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998), 1615–1622.
12. Sever, P.S., Dahlöf, B., Poulter, N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003), 1149–1158.
13. Colhoun, H.M., Betteridge, D.J., Durrington, P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004), 685–696.
14. Nakamura, H., Arakawa, K., Itakura, H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 368 (2006), 1155–1163.
15. Ridker, P.M., Danielson, E., Fonseca, F.A.H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
16. Yusuf, S., Bosch, J., Dagenais, G., et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2021–2031.
17. MESA Coordinating Center. MESA website. 2015. Available at: http://www.mesa-nhlbi.org. Accessed May 24, 2017.
18. Blaha, M.J., Budoff, M.J., DeFilippis, A.P., et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet 378 (2011), 684–692.
19. Martin, S.S., Blaha, M.J., Blankstein, R., et al. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation 129 (2014), 77–86.
20. Bittencourt, M.S., Blaha, M.J., Blankstein, R., et al. Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 63 (2014), 434–443.
21. Nasir, K., Bittencourt, M.S., Blaha, M.J., et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 66 (2015), 1657–1668.
22. Taylor, F.C., Huffman, M., Ebrahim, S., Statin therapy for primary prevention of cardiovascular disease. JAMA 310 (2013), 2451–2452.
23. Ebrahim, S., Taylor, F.C., Brindle, P., Statins for the primary prevention of cardiovascular disease. BMJ, 348, 2014, 280.
24. Ridker, P.M., MacFadyen, J.G., Fonseca, F.A.H., et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes 2 (2009), 616–623.
25. Pavlovic, J., Greenland, P., Deckers, J.W., et al. Comparison of ACC/AHA and ESC guideline recommendations following trial evidence for statin use in primary prevention of cardiovascular disease: results from the population-based Rotterdam study. JAMA Cardiol 1 (2016), 708–713.
26. Leening, M.J.G., Heeringa, J., Deckers, J.W., et al. Healthy volunteer effect and cardiovascular risk. Epidemiology 25 (2014), 470–471.
27. Wald, N.J., Law, M.R., A strategy to reduce cardiovascular disease by more than 80%. BMJ, 326, 2003, 1419.
28. Budoff, M.J., McClelland, R.L., Nasir, K., et al. Cardiovascular events with absent or minimal coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 158 (2009), 554–561.
29. Hecht, H.S., A zero coronary artery calcium score: priceless. J Am Coll Cardiol 55 (2010), 1118–1120.
30. Greenland, P., When nothing is really something: new evidence of the importance of zero coronary calcium. J Am Coll Cardio Img 8 (2015), 910–912.
31. Valenti, V., Ó Hartaigh, B., Heo, R., et al. A 15-year warranty period for asymptomatic individuals without coronary artery calcium: a prospective follow-up of 9,715 individuals. J Am Coll Cardiol Img 8 (2015), 900–909.
32. Mortensen, M.B., Fuster, V., Muntendam, P., et al. A simple disease-guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage Study. J Am Coll Cardiol 68 (2016), 881–891.
33. Blaha, M., Budoff, M.J., Shaw, L.J., et al. Absence of coronary artery calcification and all-cause mortality. J Am Coll Cardio Img 2 (2009), 692–700.
34. Rossello, X., Pocock, S.J., Julian, D.G., Long-term use of cardiovascular drugs: challenges for research and for patient care. J Am Coll Cardiol 66 (2015), 1273–1285.
35. Blaha, M.J., Silverman, M.G., Budoff, M.J., Is there a role for coronary artery calcium scoring for management of asymptomatic patients at risk for coronary artery disease? Clinical risk scores are not sufficient to define primary prevention treatment strategies among asymptomatic patients. Circ Cardiovasc Imaging 7 (2014), 398–408 discussion, 408.
36. Pletcher, M.J., Pignone, M., Earnshaw, S., et al. Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes 7 (2014), 276–284.
37. Mamudu, H.M., Paul, T.K., Veeranki, S.P., Budoff, M., The effects of coronary artery calcium screening on behavioral modification, risk perception, and medication adherence among asymptomatic adults: a systematic review. Atherosclerosis 236 (2014), 338–350.
38. Bansilal, S., Castellano, J.M., Garrido, E., et al. Assessing the impact of medication adherence on long-term cardiovascular outcomes. J Am Coll Cardiol 68 (2016), 789–801.
39. Martin, S.S., Sperling, L.S., Blaha, M.J., et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA guidelines. J Am Coll Cardiol 65 (2015), 1361–1368.
40. Pocock, S.J., Gersh, B.J., Do current clinical trials meet society's needs?: a critical review of recent evidence. J Am Coll Cardiol 64 (2014), 1615–1628.